Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription


1 Actas Urol Esp (Engl Ed)
1 Am J Clin Pathol
1 Biomed Khim
1 Biomed Res Int
2 BJU Int
1 BMJ Case Rep
1 Cancer Epidemiol
1 Cancer Immunol Immunother
1 Cancer Invest
1 Cancer Med
1 Eur Urol Focus
2 Eur Urol Oncol
2 Front Cell Dev Biol
1 Front Genet
2 Front Oncol
1 Int Braz J Urol
1 Int J Mol Sci
1 Int Urogynecol J
1 J Biochem
1 J Cell Mol Med
1 J Coll Physicians Surg Pak
1 J Endourol
1 J Exp Clin Cancer Res
1 J Genet Eng Biotechnol
1 J Infect Chemother
1 J Nanobiotechnology
2 J Proteome Res
1 JMIR Cancer
1 Methods Mol Biol
1 N Engl J Med
1 Onco Targets Ther
1 Pain Med
1 Pharmacoepidemiol Drug Saf
1 Rev Prat
1 Spinal Cord
1 Transl Androl Urol
1 Transl Oncol
1 Urol Case Rep
8 Urol Oncol
1 Wideochir Inne Tech Maloinwazyjne
1 World J Urol
1 Yonsei Med J

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Actas Urol Esp (Engl Ed)

  1. JUE JS, Alameddine M, Gonzale J, Cianci G, et al
    Risk factors, management, and survival of bladder cancer after kidney transplantation.
    Actas Urol Esp (Engl Ed). 2021 Jun 16. pii: S2173-5786(21)00075.
    PubMed         Abstract available

    Am J Clin Pathol

  2. DE JONG JJ, Narayan VM, Cronican AA, Gupta S, et al
    Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
    Am J Clin Pathol. 2021 Jun 22. pii: 6307930. doi: 10.1093.
    PubMed         Abstract available

    Biomed Khim

  3. IONOV NS, Baryshnikova MA, Bocharov EV, Pogodin PV, et al
    [Possibilities of in silico estimations for the development of pharmaceutical composition phytoladaptogene cytotoxic for bladder cancer cells].
    Biomed Khim. 2021;67:278-288.
    PubMed         Abstract available

    Biomed Res Int

  4. DENG C, Guo H, Yan D, Liang T, et al
    Pancancer Analysis of Neurovascular-Related NRP Family Genes as Potential Prognostic Biomarkers of Bladder Urothelial Carcinoma.
    Biomed Res Int. 2021;2021:5546612.
    PubMed         Abstract available

    BJU Int

  5. LOTAN Y
    Metabolic syndrome and bladder cancer.
    BJU Int. 2021;128:1-2.

  6. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.

    BMJ Case Rep

  7. GRICE P, O'Dowd S, Parkinson R, Bazo A, et al
    Bladder leiomyoma masquerading as a ureterocele.
    BMJ Case Rep. 2021;14.
    PubMed         Abstract available

    Cancer Epidemiol

  8. ZHANG L, Hsieh MC, Allison C, Devane M, et al
    Racial differences in the risk of second primary bladder cancer following radiation therapy among localized prostate cancer patients.
    Cancer Epidemiol. 2021;73:101967.
    PubMed         Abstract available

    Cancer Immunol Immunother

  9. YE R, Zeng H, Liu Z, Jin K, et al
    Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
    Cancer Immunol Immunother. 2021 Jun 21. pii: 10.1007/s00262-021-02987.
    PubMed         Abstract available

    Cancer Invest

  10. ZHOU Q, Qian Z, Ding W, Jiang G, et al
    Chronic psychological stress attenuates the efficacy of anti-PD-L1 immunotherapy for bladder cancer in immunocompetent mice.
    Cancer Invest. 2021 Jun 19:1-28. doi: 10.1080/07357907.2021.1943746.
    PubMed         Abstract available

    Cancer Med

  11. CAO J, Li J, Yang X, Li P, et al
    Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
    Cancer Med. 2021 Jun 24. doi: 10.1002/cam4.4071.
    PubMed         Abstract available

    Eur Urol Focus

  12. BENMERZOUG S, Chevalier MF, Verardo M, Nguyen S, et al
    Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Eur Urol Focus. 2021 Jun 16. pii: S2405-4569(21)00163.
    PubMed         Abstract available

    Eur Urol Oncol

  13. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Cheng L, et al
    Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brundl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology No
    Eur Urol Oncol. 2021 Jun 15. pii: S2588-9311(21)00117.

  14. GIANNARINI G, Agarwal N, Apolo AB, Briganti A, et al
    Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Jun 16. pii: S2588-9311(21)00114.
    PubMed         Abstract available

    Front Cell Dev Biol

  15. NIE Z, Chen M, Wen X, Gao Y, et al
    Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link.
    Front Cell Dev Biol. 2021;9:683940.
    PubMed         Abstract available

  16. LU JL, Xia QD, Sun Y, Xun Y, et al
    Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis.
    Front Cell Dev Biol. 2021;9:651560.
    PubMed         Abstract available

    Front Genet

  17. ZHANG P, Yang Q
    Overexpression of SHMT2 Predicts a Poor Prognosis and Promotes Tumor Cell Growth in Bladder Cancer.
    Front Genet. 2021;12:682856.
    PubMed         Abstract available

    Front Oncol

  18. DU Y, Miao W, Jiang X, Cao J, et al
    The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.
    Front Oncol. 2021;11:683951.
    PubMed         Abstract available

  19. LUO C, Ye W, Hu J, Othmane B, et al
    A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:660273.
    PubMed         Abstract available

    Int Braz J Urol

  20. KORKES F, Spiess PE, Garcia-Perdomo HA, Necchi A, et al
    Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review.
    Int Braz J Urol. 2021;47.
    PubMed         Abstract available

    Int J Mol Sci

  21. JERMAN UD, Visnjar T, Bratkovic IH, Resnik N, et al
    Attachment of Cancer Urothelial Cells to the Bladder Epithelium Occurs on Uroplakin-Negative Cells and Is Mediated by Desmosomal and Not by Classical Cadherins.
    Int J Mol Sci. 2021;22.
    PubMed         Abstract available

    Int Urogynecol J

  22. ORELLANA FM, Traete PL, de Toledo LGM
    Voiding dysfunction due to female urethral carcinoma.
    Int Urogynecol J. 2021;32:219-222.

    J Biochem

  23. GRUBA N, Stachurski L, Lesner A
    Elastolytic activity is associated with inflammation in bladder cancer.
    J Biochem. 2021 Jun 24. pii: 6308946. doi: 10.1093.
    PubMed         Abstract available

    J Cell Mol Med

  24. CHOU KY, Chang AC, Ho CY, Tsai TF, et al
    Thrombospondin-4 promotes bladder cancer cell migration and invasion via MMP2 production.
    J Cell Mol Med. 2021 Jun 17. doi: 10.1111/jcmm.16463.
    PubMed         Abstract available

    J Coll Physicians Surg Pak

  25. OZKAPTAN O, Cubuk A, Dincer E, Ipek OM, et al
    Adenocarcinoma in Orthotopic Neobladder 19 Years After Radical Cystoprostatectomy.
    J Coll Physicians Surg Pak. 2021;30:588-590.
    PubMed         Abstract available

    J Endourol

  26. IQBAL U, Elsayed AS, Jing Z, Stoeckle M, et al
    Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Endourol. 2021 Jun 17. doi: 10.1089/end.2021.0013.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  27. ZHANG J, Zhou Q, Xie K, Cheng L, et al
    Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    J Exp Clin Cancer Res. 2021;40:203.
    PubMed         Abstract available

    J Genet Eng Biotechnol

  28. KHALIFA MK, Bakr NM, Ramadan A, Abd Elwahab KM, et al
    Implications of targeted next-generation sequencing for bladder cancer: report of four cases.
    J Genet Eng Biotechnol. 2021;19:91.
    PubMed         Abstract available

    J Infect Chemother

  29. ETANI T, Asaoka M, Kondo S, Wachino C, et al
    Efficacy of fosfomycin in the prevention of postoperative infection following transurethral resection of bladder tumor during periods of limited cefazolin, cefotiam, and cefmetazole supply.
    J Infect Chemother. 2021;27:625-631.
    PubMed         Abstract available

    J Nanobiotechnology

  30. LIU J, Zhang Y, Zeng H, Wang L, et al
    Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer.
    J Nanobiotechnology. 2021;19:189.
    PubMed         Abstract available

    J Proteome Res

  31. PLYUSHCHENKO IV, Fedorova ES, Potoldykova NV, Polyakovskiy KA, et al
    Omics Untargeted Key Script: R-Based Software Toolbox for Untargeted Metabolomics with Bladder Cancer Biomarkers Discovery Case Study.
    J Proteome Res. 2021 Jun 23. doi: 10.1021/acs.jproteome.1c00392.
    PubMed         Abstract available

  32. CHEN CJ, Chou CY, Shu KH, Chen HC, et al
    Discovery of Novel Protein Biomarkers in Urine for Diagnosis of Urothelial Cancer Using iTRAQ Proteomics.
    J Proteome Res. 2021;20:2953-2963.
    PubMed         Abstract available

    JMIR Cancer

  33. PLASEK J, Weissert J, Downs T, Richards K, et al
    Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guerin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.
    JMIR Cancer. 2021;7:e25800.
    PubMed         Abstract available

    Methods Mol Biol

  34. WITZKE KE, Grosserueschkamp F, Gerwert K, Sitek B, et al
    Application of Label-Free Proteomics for Quantitative Analysis of Urothelial Carcinoma and Cystitis Tissue.
    Methods Mol Biol. 2021;2228:283-292.
    PubMed         Abstract available

    N Engl J Med

  35. BAJORIN DF, Witjes JA, Gschwend JE, Schenker M, et al
    Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
    N Engl J Med. 2021;384:2102-2114.
    PubMed         Abstract available

    Onco Targets Ther

  36. TIAN X, Zhu Q, Zhang Z
    Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
    Onco Targets Ther. 2021;14:3701-3708.
    PubMed         Abstract available

    Pain Med

  37. SOBERON JR, Awoniyi CA, Perez MA, Vasilopoulos T, et al
    Obturator Nerve Blockade vs. Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors: A Randomized Controlled Trial.
    Pain Med. 2021;22:1253-1260.
    PubMed         Abstract available

    Pharmacoepidemiol Drug Saf

  38. SADETSKY N, Chuo CY, Davidoff AJ
    Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
    Pharmacoepidemiol Drug Saf. 2021 Jun 18. doi: 10.1002/pds.5309.
    PubMed         Abstract available

    Rev Prat

  39. GROBET-JEANDIN E, Pinar U, Loriot Y, Roupret M, et al
    ["Treatment of bladder cancer with immune checkpoints inhibitors"].
    Rev Prat. 2021;71:391-395.
    PubMed         Abstract available

    Spinal Cord

  40. BOTHIG R, Kowald B, Fiebag K, Balzer O, et al
    Bladder management, severity of injury and period of latency: a descriptive study on 135 patients with spinal cord injury and bladder cancer.
    Spinal Cord. 2021 Jun 17. pii: 10.1038/s41393-021-00651.
    PubMed         Abstract available

    Transl Androl Urol

  41. FU Y, Sun S, Bi J, Kong C, et al
    Construction and analysis of a ceRNA network and patterns of immune infiltration in bladder cancer.
    Transl Androl Urol. 2021;10:1939-1955.
    PubMed         Abstract available

    Transl Oncol

  42. OKUBO K, Miyai K, Kato K, Asano T, et al
    Simvastatin-romidepsin combination kills bladder cancer cells synergistically.
    Transl Oncol. 2021;14:101154.
    PubMed         Abstract available

    Urol Case Rep

  43. MATSUI Y
    A case of inflammatory myofibroblastic tumor of the urinary bladder with emergency clinical symptoms similar to bladder cancer.
    Urol Case Rep. 2021;38:101740.
    PubMed         Abstract available

    Urol Oncol

  44. NITSCHKE K, Worst TS, von Rhade SM, Thaqi B, et al
    High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 13. pii: S1078-1439(21)00216.
    PubMed         Abstract available

  45. IGEL DA, Lee EK
    The role of technology in the perioperative management of bladder cancer patients.
    Urol Oncol. 2021 Jun 18. pii: S1078-1439(21)00179.
    PubMed         Abstract available

  46. WILLIAMS SB, Gavaghan MB, Fernandez A, Daneshmand S, et al
    Macro and microeconomics of blue light cystoscopy with CYSVIEW(R) in non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00231.
    PubMed         Abstract available

  47. PEKALA KR, Yabes JG, Bandari J, Yu M, et al
    The centralization of bladder cancer care and its implications for patient travel distance.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00187.
    PubMed         Abstract available

  48. CIVELEK AC, Niglio SA, Malayeri AA, Lin J, et al
    Clinical value of (18)FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer.
    Urol Oncol. 2021 Jun 14. pii: S1078-1439(21)00181.
    PubMed         Abstract available

  49. KUKREJA JB, Schroeck FR, Lotan Y, Gore JL, et al
    Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00215.
    PubMed         Abstract available

  50. CHOU WH, McGregor B, Schmidt A, Carvalho FLF, et al
    Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review.
    Urol Oncol. 2021 Jun 13. pii: S1078-1439(21)00223.
    PubMed         Abstract available

  51. MONTAZERI K, Dranitsaris G, Thomas JD, Curran C, et al
    An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00190.
    PubMed         Abstract available

    Wideochir Inne Tech Maloinwazyjne

  52. GAO J, Tian DW, Zhou DS, Wu CL, et al
    Flexible cystoscopy can improve anxiety and subjective feelings of bladder cancer patients during follow-up.
    Wideochir Inne Tech Maloinwazyjne. 2021;16:397-402.
    PubMed         Abstract available

    World J Urol

  53. KATAYAMA S, Mori K, Pradere B, Laukhtina E, et al
    Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer.
    World J Urol. 2021 Jun 18. pii: 10.1007/s00345-021-03740.
    PubMed         Abstract available

    Yonsei Med J

  54. KIM HJ, Chun J, Kim TH, Yang G, et al
    Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View.
    Yonsei Med J. 2021;62:569-576.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.